Triptorelin and the HPG Axis Restart Protocol — Research Guide
Triptorelin is a synthetic GnRH agonist peptide that occupies a unique position in reproductive health research — it can both stimulate and suppress the HPG (hypothalamic-pituitary-gonadal) axis depending on how it is administered. Its most studied research application in the biohacking and TRT community is the single-dose HPG axis restart protocol for restoring endogenous testosterone production after prolonged androgen-induced HPG suppression.
Understanding HPG axis suppression
The HPG axis is the hormonal cascade governing testosterone production: the hypothalamus releases GnRH in pulses, stimulating pituitary LH and FSH release, which in turn stimulates testicular testosterone production. Exogenous testosterone from TRT or anabolic androgens suppresses this cascade through negative feedback — elevated testosterone signals the hypothalamus and pituitary to reduce GnRH, LH, and FSH production, leading to testicular atrophy and reduced endogenous testosterone capacity over time. When exogenous androgens are discontinued, the suppressed HPG axis does not always recover spontaneously, or recovers slowly — leaving an extended period of low testosterone with associated symptoms.
How Triptorelin works differently from Gonadorelin and HCG
The three GnRH/HPG axis peptides in the Peptide Hub database — Gonadorelin, HCG, and Triptorelin — work through distinct mechanisms. Gonadorelin mimics the pulsatile GnRH release pattern to stimulate pituitary LH and FSH production on an ongoing basis — it maintains the HPG axis in a stimulated state during TRT to prevent atrophy. HCG bypasses the pituitary entirely, acting directly on testicular LH receptors (Leydig cells) to stimulate testosterone production — it maintains testicular function without restoring the full HPG cascade. Triptorelin, as a long-acting GnRH agonist, initially produces a powerful LH and FSH surge (the flare response) that stimulates the pituitary maximally — then, with continued receptor occupancy, causes GnRH receptor desensitization and paradoxical HPG suppression. For restart protocols, only the initial flare response is desired, achieved through single-dose administration that is metabolized before the desensitization phase dominates.
The single-dose restart protocol
The Triptorelin restart protocol uses a single intramuscular or subcutaneous injection of 0.1mg — a dose far below the 3.75mg monthly depot formulations used in prostate cancer research. At 0.1mg, Triptorelin produces a sufficient LH and FSH surge to stimulate testicular recovery without sustaining receptor occupancy long enough to produce the desensitization-driven suppression. The 4-6 week post-injection period allows assessment of LH, FSH, and total testosterone levels to determine whether HPG axis recovery has occurred. If recovery is incomplete, a second 0.1mg dose may be administered after the 4-6 week interval. See the Triptorelin research profile for full specifications.
Critical research considerations
The Triptorelin restart protocol requires physician oversight and hormonal monitoring — LH, FSH, and total testosterone measurements before and 4-6 weeks after the protocol are essential for assessing response. The timing of the protocol is critical: all exogenous androgens must be fully cleared before administration (typically 2-4 weeks after the last TRT dose, depending on the ester). Premature administration while androgens are still active will not produce the desired HPG response. HCG is sometimes used in the period between TRT discontinuation and Triptorelin administration to maintain testicular size and Leydig cell responsiveness — making the subsequent Triptorelin restart more effective. Consult a qualified healthcare professional — this is a medical protocol requiring physician supervision.